CRISPR Therapeutics Valuation
| 1CG Stock | 40.80 0.00 0.00% |
At this time, the firm appears to be fairly valued. CRISPR Therapeutics shows a prevailing Real Value of USD40.8 per share. The current price of the firm is USD40.8. Our model approximates the value of CRISPR Therapeutics from reviewing the firm fundamentals such as Current Valuation of 2.16 B, price to sales of 1,731 X, and Revenue of 436 K as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that CRISPR Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of CRISPR Therapeutics is based on 3 months time horizon. Increasing CRISPR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
CRISPR Therapeutics' intrinsic value may or may not be the same as its current market price of 40.80, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 40.8 | Real 40.8 | Hype 40.8 | Naive 40.8 |
The intrinsic value of CRISPR Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence CRISPR Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of CRISPR Therapeutics AG helps investors to forecast how CRISPR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CRISPR Therapeutics more accurately as focusing exclusively on CRISPR Therapeutics' fundamentals will not take into account other important factors: CRISPR Therapeutics Total Value Analysis
CRISPR Therapeutics AG is presently anticipated to have takeover price of 2.16 B with market capitalization of 4.99 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the CRISPR Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.16 B | 4.99 B |
CRISPR Therapeutics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of CRISPR implies not a very effective usage of assets in January.CRISPR Therapeutics Profitability Analysis
The company reported the revenue of 436 K. Net Loss for the year was (650.17 M) with profit before overhead, payroll, taxes, and interest of 0.About CRISPR Therapeutics Valuation
The stock valuation mechanism determines CRISPR Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of CRISPR Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of CRISPR Therapeutics. We calculate exposure to CRISPR Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CRISPR Therapeutics's related companies.8 Steps to conduct CRISPR Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates CRISPR Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct CRISPR Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain CRISPR Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine CRISPR Therapeutics' revenue streams: Identify CRISPR Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research CRISPR Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish CRISPR Therapeutics' growth potential: Evaluate CRISPR Therapeutics' management, business model, and growth potential.
- Determine CRISPR Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate CRISPR Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.